Bracco Imaging is launching AiMIFY, an AI-powered contrast-enhancement software developed with Subtle Medical, in the European Union (EU), and has announced a strategic partnership on contrast-enhanced CT with Avicenna.AI.
AiMIFY amplifies contrast enhancement in brain MR images acquired after injection of a gadolinium-based contrast agent, to support radiologists in detecting and assessing brain lesions, according to the company.
The collaboration with Avicenna.AI will focus on computer-assisted detection and diagnosis in brain CT angiography, Bracco said. The solution is currently in development and clinical validation at sites in the U.S. and Europe, with a U.S. Food and Drug Administration submission planned for the second half of 2026.
Both collaborations will be featured at ECR 2026 in Vienna, Austria.
